Travere Therapeutics to Participate at Upcoming Investor Conferences

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity 45th Annual Growth Conference

Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET

Citi's 2025 Biopharma Back to School Conference

Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET

2025 Wells Fargo Healthcare Conference

Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET

Cantor Global Healthcare Conference 2025

Presenting on Thursday, September 4, 2025, at 2:45 p.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

Travere Therapeutics is participating at investor conferences in August and September

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  198.79
-0.81 (-0.41%)
AAPL  255.78
-5.95 (-2.27%)
AMD  207.32
+1.38 (0.67%)
BAC  52.55
+0.03 (0.06%)
GOOG  306.02
-3.35 (-1.08%)
META  639.77
-10.04 (-1.55%)
MSFT  401.32
-0.52 (-0.13%)
NVDA  182.81
-4.13 (-2.21%)
ORCL  160.14
+3.66 (2.34%)
TSLA  417.44
+0.37 (0.09%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.